<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Poster B78: Disrupting the CD47-SIRPa Anti-Phagocytic Axis: A Novel I/O Approach

CD47 Expression Predicts Efficacy of Macrophage-Mediated Phagocytosis of Tumor Cells

Huajun Yang, Zhongliang Li, Beibei Tang, Wanqiu Zhuang, Danting Yan, Frank Xing, and Qian Shi

CrownBio 2017. Poster B78: Disrupting the CD47-SIRPa Anti-Phagocytic Axis: A Novel I/O ApproachMost human tumors express CD47 to escape macrophage surveillance. Therefore reinstating macrophage functionality in clearing tumor cells targeting CD47 has become an important strategy in immunotherapy.

CrownBio has profiled a large panel of tumor cell lines to study CD47 levels, and discovered that many tumor cells do not in fact present CD47 on their cell surface, despite gene expression data (e.g. RNAseq data) suggesting that they do.

Now, to further research into novel anti-CD47 agents, robust preclinical platforms including in vitro assays are required. To meet this need, Crown Bioscience has developed a macrophage differentiation system followed by M1/M2 activation.

Read this Poster to Discover:

  • A co-culture assay with activated macrophages and target tumor cells, plus labeling for flow cytometry, allowing the phagocytic effects of anti-CD47 agents and other related immunotherapeutics to be assessed.

  • How CD47 expression level varies in different cancer cell models.

  • That disrupting the CD47-SIRPa anti-phagocytic axis is a novel immunotherapy approach against cancer.

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.